EFFECT OF INTERLEUKIN-6 POLYMORPHISM ON FUNCTION OF
THE RENAL ALLOGRAFT FUNTION AND EFFICACY OF
IMMUNOSUPPRESSIVE THERAPY
MACIEJ KOTOWSKI 1,2*, ANNA BOGACZ 3,4, JOANNA BARTKOWIAK-WIECZOREK 5, JERZY SIENKO 2, KAROL TEJCHMAN 2, KRZYSZTOF DZIEWANOWSKI 6, MAREK OSTROWSKI 2, BOGUSŁAW CZERNY 3,8, EDMUND GRZEŚKOWIAK 5, BOGUSŁAW MACHALIŃSKI 1
1Department of General Pathology, Pomeranian Medical University, Szczecin, Poland
2Department of General Surgery and Transplantation, Pomeranian Medical University, Szczecin, Poland
3Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibres and Medicinal Plants, Poznan, Poland
4Department of Histocompatibility with Laboratory of Genetic Diagnostics, Regional Blood Centre, Poznan, Poland
5Laboratory of Experimental Pharmacogenetics, Department of Clinical Pharmacy and Biopharmacy, University of Medical
Sciences, Poznan, Poland
6Nephrology-Transplant Centre, Department of the Regional Public Hospital in Szczecin, Szczecin, Poland
7Department of General Pharmacology and Pharmacoeconomics, Pomeranian Medical University, Szczecin, Poland
*corresponding author: maciej.j.kotowski@gmail.com
DownloadDownload Full Article

Abstract:
The administration of immunosuppressive drugs affects the improvement of organ transplants. However, they can have a double
effect, because it is well established that immunosuppressive drugs may result in nephrotoxicity related to the development of
chronic graft dysfunction and acute rejection. The aim of the study was to determine a correlation between the therapeutic
effect of immunosuppressants and IL-6 -174G > C polymorphism in patients after renal transplantation. A total of 185
patients receiving cyclosporine (CsA) were involved. The genotype frequencies were determined using the real-time
polimerase chain reaction (PCR) method. The highest doses of cyclosporine were used for carriers of the GG genotype (GG:
196.00 mg vs GC: 169.70 mg and CC: 170.00 mg, p = 0.77). No such correlations were found for the determined blood
concentration of CsA, because carriers of the CC genotype had slightly lower mean drug concentration in the blood as
compared to the individuals with the GG and GC genotypes (CC: 112.41 ± 6.95 ng/mL vs GG: 119.08 ± 51.31 ng/mL and
GC: 135.24 ± 28.68 ng/mL, p = 0.78). In addition, a comparison of the IL-6 genetic variants and the biochemical parameters
found no potential risk for transplant rejection. However, the results obtained for creatinine suggest that patients with the CC
genotype and receiving CsA may be at high risk of kidney graft rejection. These results indicate that IL-6 polymorphism may
influence the dosage of immunosuppressive drugs in patients after transplantation as far as the individualization of therapy is
concerned.






Top